Teva's Copaxone Patent Battle Ends; Generics to Hit Market

Source: Seeking Alpha

Feb 02, 2017

A U.S. district court ruling invalidated four patents on Teva's multiple sclerosis therapy, Copaxone, meaning a generic version of the 40mg formulation could be on the market as soon as this month.

The ruling put a stop Teva’s strategy of switching patients from the original 20mg once-daily version of Copaxone to the newer 40mg, thrice-weekly version.

Copaxone generates a fifth of Teva’s $20 billion in annual sales.

Novartis and partner Momenta have a generic version of the 40mg dose under FDA review. Mylan also has a generic of the thrice-weekly version awaiting U.S. regulatory approval. Dr. Reddy's Laboratories and Amneal Pharmaceuticals also have 40mg products.

Read the Seeking Alpha coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments